Bayer

News

Report claims Bayer is already hunting for a new CEO

Bayer chief executive Werner Baumann has been under fire from investors since he spearheaded the acquisition of agrochemical company Monsanto for $63 billion, exposing the group to multibil

News

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

Patients

Bayer sets out a proposed basis for science-based self-care ...

The healthcare sector has a “moral imperative” to help people navigate the self-care industry, says pharma giant.

News

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.

News

Merck chases Bayer/Ionis with fast track for Factor XI drug

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short

News

DNA helix in a futuristic concept of the evolution of science and medicine.

Bayer unit BrainVectis cleared to start Huntington gene ther...

France's BrainVectis, a subsidiary of Bayer's Asklepios BioPharma (AskBio) unit, has been given the green light by regulators in France to start dosing patients with its gene therapy candid

Report claims Bayer is already hunting for a new CEO

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

Bayer sets out a proposed basis for science-based self-care ...

ESC22: Despite trial misses, Bayer preps phase 3 for asundex...

Merck chases Bayer/Ionis with fast track for Factor XI drug

Bayer unit BrainVectis cleared to start Huntington gene ther...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Bayer

Editor's Picks